EP Patent

EP2013218A2 — Raf inhibitors and their uses

Assigned to Arqule Inc · Expires 2009-01-14 · 17y expired

What this patent protects

The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disor…

USPTO Abstract

The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP2013218A2
Jurisdiction
EP
Classification
—
Expires
2009-01-14
Drug substance claim
No
Drug product claim
No
Assignee
Arqule Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.